Maximum Results
Compounded tirzepatide injection pen
GLP-1 Medication

Contains tirzepatide (compounded; not FDA-approved)

Compounded tirzepatide injection

Compounded Tirzepatide Injection

Dual-action GLP-1/GIP receptor agonist

Starting at$149

Starting at $149 for your first month; subscription auto-renews monthly at the standard plan rate until cancelled. Includes provider consultations and medication. Cancel anytime. See full pricing details.

Compounded medication: Prepared by state-licensed sterile compounding pharmacies. Individual results may vary. See full Safety Information.
In Stock — Ready to Ship
Weekly injection
|Once weekly
30-day consultation-fee refund (medication non-refundable per policy)Review us on TrustpilotTake the Quiz →
No insurance requiredCancel anytimeFree discreet shipping

Available in 39 U.S. states · Licensed providers in your state

No credit card required. If you don't qualify, you won't be charged.

About This Treatment

Compounded GLP-1/GIP receptor agonist for medically supervised weight management. Dual mechanism (GIP + GLP-1) for stronger appetite suppression vs GLP-1 alone.

How It Works

Dual GIP/GLP-1 receptor agonist that activates two hormones for stronger appetite suppression and improved insulin sensitivity.

Key Benefits

  • Dual hormone action — GIP + GLP-1
  • Strong appetite suppression
  • Supports insulin sensitivity
  • Once-weekly convenience
  • Compounded under licensed pharmacy oversight

What's Included

  • Licensed provider consultation
  • Personalized dosing protocol
  • Compounded tirzepatide injection
  • Monthly medication shipment
  • Free discreet shipping
  • HIPAA-secure messaging with care team
  • Dosage adjustments as needed
  • Dual GIP/GLP-1 receptor activation
  • 24/7 patient support
  • Cancel anytime

Medically reviewed by licensed healthcare providers in our clinical partner network · Last reviewed: April 2026

FDA Boxed Warning — Thyroid C-Cell Tumors

GLP-1 receptor agonists (including semaglutide and tirzepatide) caused thyroid C-cell tumors in rodents. It is unknown whether these medications cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC and symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).

See full Safety Information before starting therapy.

Important information

Not Sure Which Treatment Is Right for You?

Take our free assessment and a licensed provider will recommend the best option based on your health profile and goals.

Take the Quiz →